Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors

被引：0
|
作者：
Castello, A. [1 ]
Rossi, S. [1 ]
Toschi, L. [1 ]
Lopci, E. [1 ]
机构：
[1] Humanitas Clin & Res Hosp, Rozzano, MI, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPS-024
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [21] Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Babiker, Hani
    Gutierres, Barbara
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S308 - S308
  • [22] PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC
    Lau, S.
    Rabindranath, M.
    Weiss, J.
    Li, J.
    Nirmalakumar, S.
    Ruff, H.
    Boerner, S.
    Tong, L. C.
    Tsao, M.
    Pal, P.
    Cabanero, M.
    Hsu, Y. H.
    Fung, A.
    Sacher, A.
    Shepherd, F. A.
    Liu, G.
    Bradbury, P.
    Yasufuku, K.
    Czarnecka-Kujawa, K.
    Ko, H. M.
    Leighl, N.
    Schwock, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S963 - S963
  • [23] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [24] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akinleye, Akintunde
    Rasool, Zoaib
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [25] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akintunde Akinleye
    Zoaib Rasool
    Journal of Hematology & Oncology, 12
  • [26] Dynamic clonality of T cell receptor differentiate atypical progression in NSCLC patients treated with PD-1/PD-L1 inhibitors
    Han, Jiefei
    Wang, Zhijie
    Wang, Yuqi
    Chen, Si
    Bai, Hua
    Duan, Jianchun
    Wang, Jie
    CANCER RESEARCH, 2019, 79 (13)
  • [27] Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
    Yimin Wang
    Hedong Han
    Fang Zhang
    Tangfeng Lv
    Ping Zhan
    Mingxiang Ye
    Yong Song
    Hongbing Liu
    British Journal of Cancer, 2022, 127 : 948 - 956
  • [28] Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC
    Bouhamama, Amine
    Leporq, Benjamin
    Faraz, Khuram
    Foy, Jean-Philippe
    Boussageon, Maxime
    Perol, Maurice
    Ortiz-Cuaran, Sandra
    Ghiringhelli, Francois
    Saintigny, Pierre
    Beuf, Olivier
    Pilleul, Frank
    FRONTIERS IN RADIOLOGY, 2023, 3
  • [29] Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors
    Mota, Jose Mauricio
    Teo, Min Yuen
    Whiting, Karissa
    Li, Han A.
    Regazzi, Ashely M.
    Lee, Chung-Han
    Funt, Samuel A.
    Bajorin, Dean
    Ostrovnaya, Irina
    Iyer, Gopa
    Rosenberg, Jonathan E.
    JOURNAL OF IMMUNOTHERAPY, 2021, 44 (07) : 248 - 253
  • [30] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Musielak, Bogdan
    Rudzinska-Szostak, Ewa
    Berlicki, Lukasz
    Kocik, Justyna
    Grudnik, Przemyslaw
    Sala, Dominik
    Zarganes-Tzitzikas, Tryfon
    Shaabani, Shabnam
    Doemling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
12345